Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Inks HPV Screening Deal with China's KingMed Diagnostics

NEW YORK (GenomeWeb News) – Qiagen has signed a co-marketing deal in China with KingMed Diagnostics aimed at expanding access to its digene HPV test.

KingMed is China's largest independent laboratory network, according to Qiagen, and under the agreement will serve as a centralized lab. This will allow smaller hospitals and those in less-populated areas to offer the HPV test and send samples to KingMed for processing and analysis.

Victor Shi, Asia Pacific president of Qiagen, said in a statement that the agreement will bring the test to regions where it is most needed. "Qiagen and KingMed Diagnostics have had a long and fruitful collaboration which we are now significantly expanding," he added.

Qiagen said the digene HPV test was first registered in China in 2000 and is widely available in the country.

It also noted that in recognition of International Women's Day today it would donate HPV tests for the screening of several thousand underprivileged women across China.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.